Pets At Home Interim Results Show Retail Slump, Vet Growth and Turnaround Plan

Growth was driven by higher average transaction values and the continued build of Care Plan subscriptions – now with over 50% of clients on a plan. Visits were “more subdued” as more pets move into healthy mid-life, but the longer-term cohort dynamics and planned practice openings/extensions look supportive. H1 saw 5 new practices and 3 extensions; management still sees scope for 100 new practices and 100 extensions over the medium term.

Subscriptions, digital and customer metrics

• Subscriptions now 14.6% of Group consumer revenue, up from 11.4% a year ago, driven by Easy Repeat and Care Plans.
• Pets Club members fell 2.4% to 7.9m, reflecting a weaker retail active customer base.
• Average consumer value per member rose to £185, helped by vet spend.
• Puppy & Kitten sign-ups averaged c17k per week, up 13% YoY – a decent pipeline for future vet demand.

Costs, cash and the balance sheet

Operating costs were tightly managed – broadly flat excluding insurance start-up costs, and up 1.2% including them – well within guidance for no more than 5% growth this year. A restructuring is underway to remove £20m of overhead, with non-underlying costs of £6-8m in FY26 and full run-rate benefits from FY27.

Free cash flow edged up to £34.0m, but it was almost entirely driven by Vets (£53.6m) and a working capital timing benefit that unwinds in H2. Retail free cash flow was -£11.1m. Cash stood at £49.0m; adjusted net debt was £12.0m (before £338.0m of lease liabilities). The £25m buyback is 50% complete and the interim dividend is held at 4.7p.

Outlook: guidance held, H2 hinges on Retail improvement

Pets at Home keeps FY26 underlying PBT guidance at £90-100m. Within that, management expects Vet Group PBT of more than £80m. Retail is “improving sequentially” but still behind a flat market; slight positive Retail LFL is expected in H2 as the business laps soft comparatives. Insurance remains on track to launch in 2026, with FY26 losses now expected to be around £5m (from £3m). Year-end net debt is guided to c£25m and the full-year tax rate to 27-28%.

Turnaround plan: what matters and why

1) Product reset

The core issue is ranging – especially in Advanced Nutrition and accessories. Expect a shift toward faster‑growing premium propositions, more own-label innovation, and new third‑party brand partnerships. This will take time but is the biggest lever to recapture share.

2) Price discipline

Price investment is already visible and is improving value perception. It pressures margin near term but is necessary if the business is to compete with DTC brands and grocers. The key is marrying stronger value with differentiated product.

3) Execution in stores and promotions

The business has launched many initiatives; execution lagged. Management is simplifying plans, tightening promo and price change processes, and fixing the in‑store rollout of Easy Repeat.

4) Cost simplification

Overheads fall by £20m as the organisation is streamlined. That should protect profit while product changes bed in and, sensibly, is expected to have less than 12 months’ payback.

Positives vs negatives in today’s print

• Positives: Vet growth, margin and cash remain sector-leading; subscriptions are growing; digital platform now performing; dividend maintained; buyback ongoing; cost actions at pace; FY guidance unchanged.
• Negatives: Retail has lost share in a flat market, with margins squeezed; Pets Club membership down; H1 cash benefited from timing that unwinds in H2; restructuring costs of £6-8m to come; insurance start-up losses increased; CMA review still ongoing (provisional findings acknowledged).

What I’m watching into Q3

• Retail LFL trend – does Q2’s sequential improvement continue and do stores start to stabilise alongside strong online?
• Advanced Nutrition range resets – evidence of premium mix shift and own-label traction.
• Accessories – early signs that new buying and merchandising capability is landing with better sell-through.
• Vet execution – practice openings/expansions on track to underpin “>£80m” PBT.
• Cash conversion – how much of the H1 working capital inflow unwinds, and progress toward c£25m year-end net debt.
• Cost-out delivery – clarity on timing of the £20m overhead reduction and FY27 run-rate.

My take

The investment case is increasingly about whether Retail can stop the slide while the Vet engine hums along. Management is being honest about the root causes and is acting on the controllables. The price cuts, product reset and cost simplification should help, but the full effect will take time, and near-term margin pressure is the trade-off.

On the other side, Vets continue to justify a premium multiple – high margins, capital-light cash generation and clear levers for growth. With guidance intact and cash returns ongoing, the downside looks cushioned, but H2 depends on Retail’s stabilisation. If the turnaround gains traction, Pets at Home still has the assets – scale, brand, subscriptions and a first-class Vet business – to get back on the front foot.